Oral Thin Films Market Predicted to Reach US$ 7.19 Billion by 2032

The global oral thin films market is expected to grow at an 8.7% CAGR, rising from US$ 3.12 billion in 2022 to US$ 7.19 billion by the end of 2032.

The global oral thin films market has experienced significant growth in recent years, driven by their convenience, ease of use, and effectiveness in drug delivery. Oral thin films, also known as oral strips, are thin, flexible films that dissolve rapidly in the mouth when they come into contact with saliva. This innovative drug delivery system offers numerous advantages over traditional dosage forms like tablets and capsules.

Get Free Sample Copy of This Report-https://www.factmr.com/connectus/sample?flag=S&rep_id=5776

Oral Thin Films Market Growth

The growth of the oral thin films market is attributed to several key factors. First and foremost, the ease of administration makes oral thin films an attractive option for patients, particularly those who have difficulty swallowing pills or capsules. This feature is especially beneficial for pediatric and geriatric populations.

Furthermore, the rapid dissolution of oral thin films allows for quicker onset of action, making them ideal for drugs that require fast absorption and relief. This is particularly valuable in the case of acute conditions, such as pain management, allergies, and motion sickness.

In recent years, the pharmaceutical industry has witnessed a growing trend toward the development of innovative drug formulations, and oral thin films have emerged as a promising solution. The market is also driven by the increasing prevalence of chronic diseases and the need for patient-friendly dosage forms. The rise in self-medication and consumer preference for over-the-counter (OTC) drugs further fuels the demand for oral thin films.

Oral Thin Films Market Opportunities

The oral thin films market offers several opportunities for growth and innovation. Manufacturers are continually exploring new drug formulations that can be delivered through this convenient and patient-friendly dosage form. Combining multiple drugs within a single oral strip, known as polytherapy, is an emerging trend that provides enhanced therapeutic benefits and improves patient compliance.

The market also presents opportunities for expanding into new therapeutic areas, including neurology, psychiatry, and hormone replacement therapy. These areas can benefit from the rapid drug absorption and consistent dosing provided by oral thin films.

Additionally, the growing interest in herbal and nutraceutical products offers a potential market for oral thin films. These films can be used to deliver herbal and dietary supplements, capitalizing on the trend toward natural and holistic healthcare solutions.

Oral Thin Films Market Demand & Supply Trends

The demand for oral thin films is on the rise, driven by both consumers and pharmaceutical manufacturers. Consumers seek the convenience and ease of administration offered by these films, while manufacturers recognize the market potential and are investing in research and development to expand their product offerings.

Supply trends in the market involve the development of novel formulations and the enhancement of manufacturing processes to meet the increasing demand. Furthermore, supply chain optimization and strategic collaborations with contract manufacturing organizations (CMOs) are becoming prevalent to ensure a streamlined production and distribution process.

Key Companies Profiled In This Report

ZIM Laboratories Ltd.
Indivior Plc.
Aquestive Therapeutics Inc.
LIVKON Pharmaceuticals Pvt. Ltd.
Sunovion Pharmaceuticals Inc.
NAL Pharma
CURE Pharmaceutical
IntelGenx Corp.
Kyu Pharmaceutical Co. Ltd.
C.L. Pharm

Oral thin films (OTFs) are in high demand in the United States for treating various conditions, including schizophrenia, ALS, and opioid addiction. They are also being developed for long-term illnesses like migraine and Alzheimer's disease. The FDA has approved over 11 oral film products. OTFs also help pharmaceutical companies protect their products when patents expire, providing up to 3 additional years of market exclusivity, which can extend to 7 years for orphan drug candidates.

Oral Thin Films Market Notable Developments

The oral thin films market has witnessed several notable developments in recent years. Pharmaceutical companies have been actively developing and launching new products in this category. For instance, thin films for pain relief, antihistamines for allergies, and antiemetics for motion sickness are increasingly available in the market.

Additionally, regulatory approvals for oral thin films have been expanding, providing further opportunities for growth. The acceptance of this drug delivery technology by regulatory authorities has encouraged pharmaceutical companies to invest in research and development.

Oral Thin Films Market Value Chain

The value chain of the oral thin films market involves multiple stakeholders, including raw material suppliers, manufacturers, pharmaceutical companies, distributors, and healthcare providers. Raw material suppliers provide the essential components required to produce the thin films, such as polymers, plasticizers, and active pharmaceutical ingredients.

Manufacturers are responsible for the production of oral thin films, including formulation development, manufacturing, and quality control. Pharmaceutical companies collaborate with manufacturers to develop and commercialize products based on their drug formulations.

Distributors play a crucial role in the supply chain by distributing oral thin film products to pharmacies, healthcare facilities, and retailers. Healthcare providers, including doctors and pharmacists, recommend and prescribe these products to patients, ensuring the delivery of the intended therapeutic benefits.

Competitive Landscape

The competitive landscape in the oral thin films market is shaped by key players who focus on new product launches with advanced technology and strategic expansion through activities like mergers, acquisitions, partnerships, and collaborations.

For instance, in August 2020, ZIM Laboratories Ltd. entered into a licensing agreement with Hypera Pharma Group to introduce a novel oral thin film for vitamin D3.

In March 2021, Aquestive Therapeutics Inc. presented a comprehensive overview of its PharmFilm® oral sublingual film designed for epinephrine administration, showcasing its potential in treating allergic reactions, including anaphylaxis.

Get Customization on this Report for Specific Research Solutions -https://www.factmr.com/connectus/sample?flag=RC&rep_id=5776

The oral thin films market continues to grow as a result of the convenience, effectiveness, and patient-friendly nature of this drug delivery system. Opportunities for expansion and innovation abound, and the market is expected to witness further developments in the coming years, making oral thin films a notable player in the pharmaceutical industry.

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we delivers deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empowers businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.

This release was published on openPR.